公开(公告)号：DE2823060C2

公开(公告)日：1988-08-11

申请号：DE2823060

申请日：1978-05-26

Applicant: THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE, WASHINGTON, D.C., US

Inventor： SNYDER, JAMES JACOB, CLARKSBURGH, MD., US

IPC: G01J3/45 ,  G01J9/00 ,  G01J9/02

公开(公告)号：BRPI0309631B1

公开(公告)日：2021-07-20

申请号：BRPI0309631

申请日：2003-04-25

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVIC

Inventor： BARRY FALGOUT ,  BRIAN R MURPHY ,  JOSEPH BLANEY ,  KATHRYN HANLEY ,  LEWIS MARKOFF ,  STEPHEN S WHITEHEAD

IPC: A61K39/42 ,  C12N15/09 ,  A61K20060101 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/295 ,  A61P31/14 ,  C07H21/00 ,  C07H21/04 ,  C12N7/00 ,  C12N7/04

Abstract: vacina tetravalente da dengue contendo uma deleção comum de 30 nucleotídeos na utr-3' dos tipos de dengue 1, 2, 3 e 4, ou de vírus antigênicos quiméricos da dengue 1, 2, 3, e 4. a invenção se refere a uma vacina tetravalente do vírus da dengue contendo uma deleção comum de 30 nucleotídeos ( (delta) 30) na região não traduzida 3' do genoma de sorotipos do vírus da dengue 1, 2, 3, e 4 ou de vírus antigênicos quiméricos da dengue de sorotipos 1, 2, 3, ou 4.

公开(公告)号：MY181496A

公开(公告)日：2020-12-23

申请号：MYPI2013000956

申请日：2007-10-30

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES

Inventor： TARASOVA NADYA ,  DEAN MICHAEL ,  LOU HONG

Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided. Methods of inhibiting proliferation of a diseased cell, treating or preventing cancer, treating a neoplasm or psoriasis, and inhibiting the expression of genes involved in the Hedgehog signaling pathway, thereby inhibiting the Hedgehog signaling pathway, are furthermore provided by the invention. (Figure 1)

公开(公告)号：CA2662012C

公开(公告)日：2018-06-19

申请号：CA2662012

申请日：2007-08-30

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES

Inventor： LOBANENKOV VICTOR V ,  PUGACHEVA ELENA ,  LOUKINOV DMITRI

IPC: C12N15/12 ,  A61K31/713 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61P37/04 ,  C07K14/47 ,  C07K16/18 ,  C40B40/06 ,  C40B40/10 ,  G01N33/53 ,  G01N33/564 ,  G01N33/574 ,  G01N33/68 ,  G06F19/28

Abstract: A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.

公开(公告)号：HUS1600050I1

公开(公告)日：2017-06-28

申请号：HUS1600050

申请日：2016-12-07

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AN

IPC: A61K45/00 ,  A61K31/7052 ,  A61K38/00 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395 ,  A61P25/00 ,  A61P37/02 ,  C07K16/28

公开(公告)号：CY1115481T1

公开(公告)日：2017-01-04

申请号：CY141100653

申请日：2014-08-13

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN

Inventor： MARTIN ROLAND ,  MCFARLAND HENRY F ,  BIELEKOVA BIBIANA

IPC: A61K35/30 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: Εδώαποκαλύπτεταιμιαμέθοδοςγιατηθεραπείαενόςυποκειμένουμεπολλαπλήσκλήρυνση. Σεμιαενσωμάτωση, παρέχεταιμιαμέθοδοςγιατηθεραπείαενόςυποκειμένουμεπολλαπλήσκλήρυνσηπουπεριλαμβάνειτηχορήγησηστουποκείμενομιαςθεραπευτικώςαποτελεσματικήςποσότηταςαπόένανανταγωνιστήτουυποδοχέατηςΙL-21, όπουτουποκείμενοαπέτυχενααποκριθείσεθεραπευτικήαγωγήμεβήταιντερφερόνη, θεραπεύονταςέτσιτουποκείμενο.

公开(公告)号：CA2776054C

公开(公告)日：2016-08-30

申请号：CA2776054

申请日：1999-07-27

Applicant: UNIV CALIFORNIA ,  THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN

Inventor： ZUKER CHARLES S ,  ADLER JON ELLIOTT ,  LINDEMEIER JUERGEN ,  RYBA NICK ,  HOON MARK

IPC: C12N15/12 ,  G01N33/50 ,  C07K14/705 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/02 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/00 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566

Abstract: The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors.

公开(公告)号：ES2571219T3

公开(公告)日：2016-05-24

申请号：ES10006835

申请日：2002-01-25

Applicant: THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES

Inventor： GUPTA SHANKER

IPC: A61K9/19 ,  C07F5/02 ,  A61K31/69 ,  A61K38/00 ,  A61K38/05 ,  A61K38/14 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07C7/00 ,  C07F5/04 ,  C07F5/05 ,  C07H9/00 ,  C07K5/06 ,  C07K5/062 ,  C07K5/065 ,  C07K5/078 ,  C07K5/08 ,  C07K5/083 ,  C07K5/097 ,  C07K5/117 ,  C07K7/02 ,  C07K9/00

Abstract: Polvo liofilizado que comprende manitol y un compuesto de fórmula (1):**Fórmula** en la que: P es hidrógeno o un resto de protección de grupo amino; R es hidrógeno o alquilo de C1-12; A es 0, 1, ó 2; R1, R2, y R3 son cada uno independientemente hidrógeno, alquilo de C1-12, cicloalquilo de C3-12, arilo de C6-14, o -CH2- R5; R5, en cada caso, es arilo de C6-14, aril (C6-14) alquilo (C1-12), alquil (C1-12) arilo (C6-14), cicloalquilo de C3-12, heterociclilo que comprende de 3 a 8 átomos, en el que uno o más átomos se seleccionan entre N, O y S, heteroarilo que comprende de 5 a 14 átomos, en el que 1-4 átomos se seleccionan entre N, O y S, o -W-R6, en el que W es un calcógeno y R6 25 es alquilo de C1-12; en la que la porción de anillo de cualquiera de dichos arilo, aralquilo, alquilarilo, cicloalquilo, heterociclilo, o heteroarilo en R1, R2, R3, o R5 puede estar opcionalmente sustituida; y Z1 y Z2 conjuntamente forman un resto derivado de manitol, en el que el átomo unido al boro en cada caso es un átomo de oxígeno, y en el que el compuesto de fórmula (1) está liofilizado y en el que dicho compuesto es un éster de manitol de ácido N- (2-piracino)carbonil-L-fenilalanina-L-leucina borónico.

公开(公告)号：AU2007348394B2

公开(公告)日：2013-08-15

申请号：AU2007348394

申请日：2007-03-07

Applicant: FUTURE MEDICINE CO LTD ,  GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

Inventor： KIM HEA OK ,  CHOE SEUNG AH ,  JEONG LAK SHIN ,  JACOBSON KENNETH A

IPC: C07D473/34 ,  A61K31/4985

Abstract: Disclosed are adenosine derivatives, methods for the synthesis thereof, and pharmaceutical compositions for the prevention and treatment of inflammatory diseases, comprising the same as an active ingredient. The adenosine derivatives have high binding affinity and selectivity for adenosine receptors, especially for A3 adenosine receptors and act as A3 adenosine receptor antagonists, and exhibit anti-inflammatory activity. Thus, the adenosine derivatives are useful in the prevention and treatment of inflammatory diseases.

公开(公告)号：AU2006279951B2

公开(公告)日：2013-02-14

申请号：AU2006279951

申请日：2006-08-10

Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY

Inventor： SUBRAMANIAN SANKARAN ,  MITCHELL JAMES B ,  MATSUMOTO KEN-ICHIRO ,  WINK DAVID A ,  HYODO FUMINORI ,  CHERUKURI MURALI K ,  COOK JOHN A ,  KORETSKY ALAN P

IPC: A61B5/05

Abstract: Disclosed is a method for determining the redox status of a region of interest in an animal tissue. The method includes administering a nitroxyl contrast agent to the region of interest, obtaining a magnetic resonance image of the region of interest, determining the amount of reduced nitroxyl contrast agent in the region of interest, and thereby determining the redox status of the region of interest.